

Referencias

1. Global Database on Body Mass Index. an interactive surveillance tool for monitoring nutrition transition. Disponible en: <http://apps.who.int/bmi/index.jsp>
2. OMS. Nota descriptiva N°311. Obesidad y sobrepeso. Disponible en: <http://www.who.int/mediacentre/factsheets/fs311/es/index.html>
3. WHO. Global database of body mass index. Disponible en: <http://apps.who.int/bmi/index.jsp>
4. Ministerio de la Protección Social. Encuesta Nacional de Salud, 2007. Disponible en: <http://www.minproteccion-social.gov.co/Documentos%20y%20Publicaciones/Encuesta%20Nacional.pdf>
5. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among U.S. adults, 1999–2000. *JAMA* 2002;288:1723–7.
6. Popkin BM. The nutrition transition and its health implications in lower income countries. *Public Health Nutr* 1998;1:5–21.
7. Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. *N Engl J Med* 2005;352:1138–45.
8. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. *Hypertension* 2007;49(1):69–75.
9. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity related health risk factors, 2001. *JAMA* 2003;289:76–9
10. Aldhahi W, Handy O. Adipokines, Inflammation, and the Endothelium in Diabetes. *Current Diabetes Reports* 2003;3:293–298
11. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or intervention or metformin. *N Engl J Med* 2002;346:393–403.
12. Poirier P, Martin J, Marceau P, et al. Impact of bariatric surgery on cardiac structure, function and clinical manifestations in morbid obesity. *Expert Rev Cardiovasc Ther* 2004;2(2):193–201.
13. Frayn K, Karpe F, Fielding B, et al. Integrative physiology of human adipose tissue. *Int J Obes* 2003;27:875–88
14. Elfhag K, Rossner S. Who succeeds in maintaining weight loss? A conceptual review of factors associated with weight loss maintenance and weight regain. *Obes Rev* 2005;6: 67–85.
15. O' Rahilly S, Farooqi IS. Genetics of obesity. *Philos Trans R Soc Lond B Biol Sci* 2006;361:1095–1105.
16. Celi FS. Brown Adipose Tissue – When it pays to be inefficient. *N Engl J Med* 2009;360:1553–56.
17. Farmer S. Molecular determinants of brown adipocyte formation and function. *Genes Dev* 2008;22:1269–75.
18. Lizcano F, Vargas D. EID1-induces brown-like adipocyte traits in white 3T3-L1 pre-adipocytes. *Biophys Biochem Res Commun* 2010;398:160–165.

19. Dall N, Matakı C, Coste A, et al. Adipose tissue-specific inactivation of the retinoblastoma protein protects against diabetes because of increased energy expenditure. *PNAS* 2007;104:10703-708.
20. Casals-Casas C, Desvergne B. Endocrine disruptors: From endocrine to metabolic disruption. *Annu Rev Physiol* 2011;73: 23.1-23.28.
21. Razquin C, Martı A, Martınez JA. Evidences on three relevant obesogenes: MC4R, FTO, and PPARg. Approaches for personalizad nutrition. *Mol Nutr Food Res* 2010; DOI: 10.1002/mnfr.201000445.
22. Qi L, Cho YA. Gene-environment interaction and obesity. *Nutr Rev* 2008;66: 684-694.
23. Hanley B, Dijane J, Fewtrell M, et al. Metabolic imprinting, programming and epigenetics – a review of present priorities and future opportunities. *Br J Nutr* 2010;104 Suppl 1:S1-25.
24. Szczepanska-Sadowska E, cudnoch-Jedrzejewska A, Ufnal M, Zera T. Brain and cardiovascular diseases: common neurogenic background of cardiovascular, metabolic and inflammatory diseases. *J Physiol Pharmacol* 2010;61: 509-521.
25. Halford JCG, Boyland EJ, Blundell JE, et al. Pharmacological Management of appetite expresi3n in obesity. *Nat Rev Endocrinol* 2010;6:255-259.
26. Finlayson G, King N, Blundell JE. Liking vs wanting food: importance for human appetite control and weight regulation. *Neurosci Biobehav Rev* 2007; 31: 987-1002.
27. Daniel H. Bessesen. Update on Obesity. *J Clin Endocrinol Metab*, June 2008, 93(6):2027–2034.
28. Obesity. Preventing and managing the Global epidemic of obesity. Report of the world health organization consultation of obesity WHO. Geneva. 3-5 June 2000.
29. McDonald SD, Han Z, Mulla S, Beyene J; Knowledge Synthesis Group. Overweight and obesity in mothers and risk of preterm birth and low birth weight infants: systematic review and meta-analyses. *BMJ*. 2010 Jul 20; 341:c3428.
30. American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Mechanick JI, Kushner RF, Sugerman HJ, Gonzalez-Campoy JM, Collazo-Clavell ML, Spitz AF, Apovian CM, Livingston EH, Brolin R, Sarwer DB, Anderson WA, Dixon J, Obesity (Silver Spring). 2009 Apr; 17 Suppl 1:S1-70.
31. Normas de atenci3n m3dica para el manejo cientıfico de sobrepeso y obesidad, funcoebes 2011 en prensa.
32. Federaci3n Latinoamericana de Nutrici3n Parenteral y Enteral: Evaluaci3n del Estado Nutricional en Paciente Hospitalizado. Mayo, 2008. Disponible en: www.aanep.com, consultada en noviembre de 2010.
33. Principios de orientaci3n para la alimentaci3n complementaria del ni3o amamantado. Organizaci3n Panamericana de la Salud, Washington, DC 2003. ISBN 92 75 32460 3.
34. Encuesta Nacional de Salud ENS 2007. Uni3n Temporal SEI S.A. – Pontificia Universidad Javeriana 890-Observatorio de Salud P3blica de Santander.

35. Stephen R. Daniels, Marc S. Jacobson, Brian W. McCrindle, Robert H. Eckel and, Brigid McHugh Sanner: American Heart Association Childhood Obesity Research Summit Report. *Circulation* 2009;119:489-517.
36. Julia Steinberger, Stephen R. Daniels, Robert H. Eckel, Laura Hayman, Robert H. Lustig, Brian McCrindle and Michele L. Mietus-Snyder: Progress and Challenges in Metabolic Syndrome in Children and Adolescents: A Scientific Statement From the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. *Circulation* 2009;119:628-647.
37. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults (NHLBI & NAASO 2000). Disponible en: http://www.nhlbi.nih.gov/guidelines/obesity/prctgd_c.pdf.
38. Anthony N. Fabricatore and Thomas A. Wadden: Obesity. *Annu Rev Clin Psychol* 2006;2:357-77.
39. Wadden TA, Butryn ML. Behavioral treatment of obesity. *Endocrinol Metab Clin N Am* 2003;32:981-1003.
40. Van Gaal LF, Broom JI, Enzi G, Toplak H. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. *Eur J Clin Pharmacol* 1998;54:125-32.
41. Maggard MA, Shugarman LR, Suttrop M, Maglione M, Sugarman HJ, et al. Meta-analysis: surgical treatment of obesity. *Ann Intern Med* 2005;142:547-59.
42. Roger A. Shewmake, Mark K. Huntington. Nutritional Treatment of Obesity. *Prim Care Clin Office Pract* 2009;36:357-377.
43. Nordmann AJ, Nordmann A, Briel M, et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. *Arch Intern Med* 2006;166(3):285-93.
44. Foster GD, Wyatt HR, Hill JO, et al. A randomized trial of a low-carbohydrate diet for obesity. *N Engl J Med* 2003;348:2082-90.
45. Gal Dubnov-Raz G., Berry E. The Dietary Treatment of Obesity. *Endocrinol Metab Clin N Am* 2008;37:873-886.
46. Frank M. Sacks, M.D., George A. Bray, M.D., Vincent J. Carey, Ph.D., Steven R. Smith, M.D., Donna H. Ryan, M.D., Stephen D. Anton, Ph.D., et al. Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates. *N Engl J Med* 2009;360:859-73.
47. O'Gorman D J., Krook A. Exercise and the Treatment of Diabetes and Obesity. *Endocrinol Metab Clin N Am* 2008;37:887-903.
48. Ross R, Dagnone D, Jones PJ, et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. *Ann Intern Med* 2000;133:92-103.
49. Wolf AM., Woodworthb K. Obesity Prevention: Recommended Strategies and Challenges. *The American Journal of Medicine* 2009;122:S19-S23.
50. Van DorstenB., Lindley M. Cognitive and Behavioral Approaches in the Treatment of Obesity. *Endocrinol Metab Clin N Am* 2008;37:905-922.
51. Rucker D, Padwal R, Li SK, Curioni C, Lau. Long term pharmacotherapy for obesity and overweight: update meta-analysis. *BMJ* 2007;335(7631):1194-1199.

52. Padwal R, Kezouh A, Levine M, Etminan M. Long term pharmacotherapy for obesity and overweight: update meta-analysis. *BMJ* 2007;335(7631):1194-1199.
53. Padwal R, Kezouh A, Levine M, Etminan M. Long term persistence with orlistat and sibutramine in a population – based cohort. *Int J. Obes. (Lond)* 31 (10), 1567 – 1570 (2007).
54. US FDA. Orlistat (marketed as Alli and Xenical): early communication about an ongoing safety review, update 24 August 2009.
55. US Food and Drug Administration Early Communication about an Ongoing Safety Review of Meridia (Sibutramine hydrochloride) Link. (Accessed November 2009).
56. www.medscape.com/viewarticle, October 08, 2010, Robert Lowes.
57. Smith SR, Weissman, NJ, Stubbe S, Anderson CM, Shanahan W. Lorcaserin reduces bodyweight in obese and overweight subjects: behavioral modification and lorcaserin for overweight and obesity management, the BLOOM trial. American Diabetes Association's 69th Scientific Sessions. New Orleans, LA, USA, June 5-9, 2009.
58. Sociedad Española de Cirugía de la Obesidad, Recomendaciones de la SECO para la práctica de la cirugía bariátrica (Declaración de Salamanca), *Cir Esp* 2004;75(5):312-4.
59. Salvador J., Fruhbeck G., Regulacion de la ingesta alimentaria: una perspectiva clínica. *Endocrinol Nutr.* 2005;52(8):404-30.
60. Cummings, Shanon, Ghrelin and gastric bypass: Is there a hormonal contribution to surgical weight loss?. *J Clin Endocrinol Metab* July 2003;88 (7):2999-3002.
61. Ochner, CN; Gibson, C; Shanik, M; Goel, V; Geliebter, A, Changes in neurohormonal gut peptides following bariatric surgery (Review) International Journal of Obesity Publish Ahead of Print, published online before print, 15 July 2010 .
62. Adler, Joshua, Cheng, Hugo, Preoperative Evaluation and perioperative management in bariatric surgery, in Camacho P, Gharib H, Sizemore Glen W, Lippincott Williams and Wilkins, 2007.
63. Palma Moya M., Quesada Charneco M., Fernandez Soto M.L., Transtornos nutricionales tras cirugía bariátrica y su tratamiento. *Endocrinol Nutr* 2007;54(Supl 2):42-7.
64. Mechanick J., Brett Elise M, Nutritional deficiencies following bariatric surgery: What have we learned? *Obes Surg* 2005;15:145-154.
65. Heber D; Greenway F.; Kaplan L.; Livingston E. Salvador J.; Still C. Endocrine and Nutritional Management of the Post-Bariatric Surgery Patient: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab* 2010;95(11):4823-4843.
66. Garcia-Lorda P, Hernandez Gonzalez M, Blanco Blasco J.S., Figueredo R, Sabench Pereferer F., Balanza Roure R., et al, Seguimiento postoperatorio de la obesidad morbida: aspectos quirúrgicos y nutricionales. *Cir Esp* 2004;75(5):305-11.
67. Sanchez Hernandez J, Ybarra J, Perez A, Hipovitaminosis D en pacientes afectos de obesidad mórbida: efectos de la cirugía bariátrica. *Rev Esp Obes* 2006;4(5):275-83.

68. Kushner R., Micronutrient deficiencies and bariatric surgery. *Obesity and nutrition* 2007;405-11.
69. Fujoka K.; Follow up of nutritional and metabolic problems after bariatric surgery. *Diabetes Care* 2005;28(2):481-3.
70. Kelly J Tarnoff M, Shikira S, Thayer B, Jones, D Amour R et al Best practice recommendations for surgical care in weight loss surgery. *Obesity Research* 2006;13(2):227-32.
71. Halford JC. Obesity drugs in clinical development. *Curr Opin Investig Drugs* 2006 Apr;7(4):312-8.
72. Halford JC, Boyland EJ, Blundell JE, Kirkham TC, Harrold JA. Pharmacological management of appetite expression in obesity. *Nat Rev Endocrinol* 2010 May;6(5):255-69.
73. Weintraub M, Sundareshan PR, Madan M, Schuster B, Balder A, Lasagna L, et al. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. *Clin Pharmacol Ther* 1992;51(5):586-94
74. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. *N Engl J Med* 1997;337(9):581-8
75. Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR; APD356-004 Study Group. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. *Obesity* (Silver Spring) 2009;17(3):494-503.
76. Bays HE. Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease. *Expert Rev Cardiovasc Ther* 2009;7(11):1429-45
77. Astrup A, Meier DH, Mikkelsen BO, Villumsen JS, Larsen TM. Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease. *Obesity* (Silver Spring) 2008;16(6):1363-9.
78. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. *Lancet* 2008;372(9653):1906-13
79. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. *Diabetes* 2004;53(5):1187-94.
80. Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courrèges JP, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. *Diabetes Care* 2007;30(6):1608-10.
81. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. *J Clin Invest* 1998;101(3):515-20.
82. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al.; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. *Lancet* 2009;374(9701):1606-16.

83. Padwal R. Cetilistat, a new lipase inhibitor for the treatment of obesity. *Curr Opin Investig Drugs* 2008;9(4):414-2.
84. Kopelman P, Groot Gde H, Rissanen A, Rossner S, Toubro S, Palmer R, et al. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). *Obesity* (Silver Spring) 2010;18(1):108-15.
85. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. *Obes Res* 2002;10(7):633-41.
86. Lee MW, Fujioka K. Naltrexone for the treatment of obesity: review and update. *Expert Opin Pharmacother* 2009;10(11):1841-5
87. Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, et al. Rational design of a combination medication for the treatment of obesity. *Obesity* (Silver Spring) 2009;17(1):30-9
88. Lee MW, Fujioka K. Naltrexone for the treatment of obesity: review and update. *Expert Opin Pharmacother* 2009;10(11):1841-5
89. Padwal R. Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. *Curr Opin Investig Drugs* 2009;10(10):1117-25
90. Oommen KJ, Mathews S. Zonisamide: a new antiepileptic drug. *Clin Neuropharmacol* 1999;22(4):192-200
91. Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. *JAMA* 2003;289(14):1820-5
92. Astrup A, Toubro S. Topiramate: a new potential pharmacological treatment for obesity. *Obes Res* 2004;12 Suppl:167S-73S.
93. Simpson KA, Martin NM, Bloom SR. Hypothalamic regulation of food intake and clinical therapeutic applications. *Arq Bras Endocrinol Metabol* 2009;53(2):120-8
94. Ravussin E, Smith SR, Mitchell JA, Shringarpure R, Shan K, Maier H, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. *Obesity* (Silver Spring) 2009;17(9):1736-43
95. Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, Weyer C. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. *Diabetes Care* 2008;31(9):1816-23
96. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. *JAMA* 1999;282(16):1568-75
97. Rosenbaum M, Goldsmith R, Bloomfield D, Magnano A, Weimer L, Heymsfield S, et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. *J Clin Invest* 2005;115(12):3579-86.
98. Trevaskis JL, Coffey T, Cole R, Lei C, Wittmer C, Walsh B, et al. Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms. *Endocrinology* 2008;149(11):5679-87